In addition, the last V5 version of BOADICEA incorporates the effects of pathogenic variants (PVs), not only in BRCA1 and BRCA2 genes, but also in PALB2, CHEK2, ATM and BARD1 for the breast cancer model and RAD51D, RAD51C and BRIP1 for the ovarian cancer model [19]. This evidence concerns the gene BARD1 and ovarian carcinoma.